Organ Transplants News
-
GFL employees participate in plasma donation drive
GFL recently partnered with Canadian Blood Services to organize a plasma donation drive in honor of the newly opened plasma donor center near GFL’s Vaughan, Ontario, head office. GFL employees donated their plasma with the goal of helping patients in local hospitals who require this life-saving component in blood. “It was amazing to see our team come together to support the ...
-
CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
CD Genomics is a leading global life sciences company committed to providing the research community with high-quality long-read sequencing services, from Oxford Nanopore to PacBio SMRT sequencing. The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient ...
By CD Genomics
-
Neovii and Fosun Pharma Enter into an Exclusive Agreement
Neovii Pharmaceuticals AG (“Neovii”), a Swiss based global specialty-care biopharmaceutical company, and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd (“Fosun Pharma Industry”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, Stock Code: 600196.SH, 02196.HK), a global pharmaceutical and healthcare industry group ...
-
Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China
Shanghai, China and Rapperswil, Switzerland) Shanghai Fosun Pharma (Group) Co. (“Fosun Pharma”, stock code : 600196.SH; 02196.HK) announced that Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”), a controlled subsidiary, signed an exclusive sales agency and development agreement with Switzerland ’s Neovii Pharmaceuticals ...
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
-
OnLume Surgical Awarded $2 Million Grant from National Cancer Institute to Advance the Development of its Novel Fluorescence-Guided Surgery Device
OnLume Inc., an early stage medical imaging company with unique technology for improving surgical precision, has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary device for Fluorescence-Guided Surgery (FGS). OnLume has developed novel FGS imaging technology to illuminate critical ...
By OnLume Inc.
-
OnLume Surgical Participates in Clinical Trial Combining Fluorescence-Guided Surgery Imaging Device with Alume’s Novel Nerve-Targeting Agent
OnLume Inc., a Madison, Wisconsin-based medical imaging company with unique technology for improving surgical precision in the operating room, has announced the start of participation in a clinical trial combining its fluorescence-guided surgery (FGS) imaging device with a novel nerve-targeting agent. OnLume has unique FGS imaging technology to illuminate critical anatomy in real time during ...
By OnLume Inc.
-
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released ...
By AlloVir
-
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiation and ...
-
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) ...
-
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “Seres continued to make important progress toward bringing SER-109 to patients suffering with recurrentC. difficileinfection (rCDI). Given the robust profile of SER-109 ...
-
SQI Diagnostics - Lung Health Diagnostic Testing
Eric Brouwer, Ph.D., Chief Scientific Officer at SQI Diagnostics, a company focused on the science of lung health, discusses the development and manufacture of respiratory health and precision medicine tests. Their tests simplify and improve COVID-19 mobile PCR, Point of Care antigen testing and antibody monitoring, Rapid Acute Lung Injury testing, donor organ transplant informatics, and ...
-
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
-
`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug
Bilirubin, which causes jaundice in humans, has been in the spotlight as an anti-inflammatory substance since the 1930s. The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the Nobel Prize in Physiology or Medicine. Attempts to drug ...
-
NEC OncoImmunity publishes a unique HLA typing technology that discovers new HLA alleles, and tumor specific HLA alleles
The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI. NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing ...
-
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional virus-specific T cell ...
By AlloVir
-
The Sunday Times - Sir Richard Branson & co pick their start-ups of 2019
These are the start-ups that most impressed Britain’s top entrepreneurs and investors in 2019. There was a technology theme to the selections, while several on our panel of small business champions picked companies, they claimed were tackling some of the world’s biggest problems by treating Alzheimer’s disease and broadening access to education. ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Biostage Hires David Green as Chief Executive Officer
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced it has hired David Green as its Chief Executive Officer and appointed Mr. Green as Chairman of the Board of Directors (the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you